Paper35836769
Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China.
Zhao X and 11 others. J Clin Transl Hepatol, 2022. Cited by 14 papers, by iCite.
Cite this record
ConductScience Library. Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China. Papers, record 35836769. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35836769
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28418296 | Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China. | Emerg Infect Dis | 2017 | https://conductscience.org/library/papers/28418296 | PubMed |
| 2 | 25164003 | The global burden of liver disease: the major impact of China. | Hepatology | 2014 | https://conductscience.org/library/papers/25164003 | PubMed |
| 3 | 34590058 | Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China. | Lancet Reg Health West Pac | 2021 | https://conductscience.org/library/papers/34590058 | PubMed |
| 4 | 35300634 | Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis. | BMC Cancer | 2022 | https://conductscience.org/library/papers/35300634 | PubMed |
| 5 | 29599078 | Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. | Lancet Gastroenterol Hepatol | 2018 | https://conductscience.org/library/papers/29599078 | PubMed |
| 6 | 32077604 | Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analogues. | Liver Int | 2020 | https://conductscience.org/library/papers/32077604 | PubMed |
| 7 | 31915601 | Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B. | J Clin Transl Hepatol | 2019 | https://conductscience.org/library/papers/31915601 | PubMed |
| 8 | 31941257 | [The guidelines of prevention and treatment for chronic hepatitis B (2019 version)]. | Zhonghua Gan Zang Bing Za Zhi | 2019 | https://conductscience.org/library/papers/31941257 | PubMed |
| 9 | 33197397 | Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. | Lancet Gastroenterol Hepatol | 2021 | https://conductscience.org/library/papers/33197397 | PubMed |
| 10 | 26268687 | Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: a population-based, cross-sectional study. | Lancet Infect Dis | 2016 | https://conductscience.org/library/papers/26268687 | PubMed |
| 11 | 32255486 | Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning. | Clin Infect Dis | 2021 | https://conductscience.org/library/papers/32255486 | PubMed |
| 12 | 33414625 | Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs. | Ann Gastroenterol | 2021 | https://conductscience.org/library/papers/33414625 | PubMed |
| 13 | 12512250 | New approaches to analysing prescription data and to transfer pharmacoepidemiological and evidence-based reports to prescribers. | Pharmacoepidemiol Drug Saf | 2002 | https://conductscience.org/library/papers/12512250 | PubMed |
| 14 | 35216027 | Current Trend in Antiviral Therapy for Chronic Hepatitis B. | Viruses | 2022 | https://conductscience.org/library/papers/35216027 | PubMed |
| 15 | 28620797 | Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. | Hepatol Int | 2017 | https://conductscience.org/library/papers/28620797 | PubMed |
| 16 | 31956236 | "4+7" city drug volume-based purchasing and using pilot program in China and its impact. | Drug Discov Ther | 2019 | https://conductscience.org/library/papers/31956236 | PubMed |
| 17 | 31231938 | Impact of reimbursement program on liver-related mortality in patients with chronic hepatitis B in Beijing, China. | J Dig Dis | 2019 | https://conductscience.org/library/papers/31231938 | PubMed |
| 18 | 34760861 | The Effects of the National Centralized Drug Purchasing Pilot Program on Nucleos(t)ide Analogs in Shenzhen City: An Interrupted Time Series Analysis. | Front Public Health | 2021 | https://conductscience.org/library/papers/34760861 | PubMed |
| 19 | 30992636 | Countdown to 2030: eliminating hepatitis B disease, China. | Bull World Health Organ | 2019 | https://conductscience.org/library/papers/30992636 | PubMed |
| 20 | 29405329 | Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. | Hepatology | 2018 | https://conductscience.org/library/papers/29405329 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42092899 | Analysis of the impact of national centralized volume-based procurement drug policy on the market dynamics of tuberculosis drugs. | BMC Health Serv Res | 2026 | https://conductscience.org/library/papers/42092899 | PubMed |
| 42050466 | Medication adherence and associated factors in patients with chronic hepatitis B in Zhejiang Province, Eastern China. | BMC Public Health | 2026 | https://conductscience.org/library/papers/42050466 | PubMed |
| 41787443 | Impact of a National Volume-Based Procurement Policy in China on purchase of nucleoside/nucleotide analog drugs for the treatment of chronic hepatitis B virus infection. | BMC Public Health | 2026 | https://conductscience.org/library/papers/41787443 | PubMed |
| 41306363 | Impact of Alanine Transaminase Thresholds on Treatment Eligibility of Patients with Chronic Hepatitis B: A Cross-sectional Study of the China Registry of Hepatitis B. | J Clin Transl Hepatol | 2025 | https://conductscience.org/library/papers/41306363 | PubMed |
| 41060358 | A Real-World Pharmacological Assessment of Tenofovir Amibufenamide and Tenofovir Alafenamide in 48-Week Chronic Hepatitis B Treatment: Efficacy, Safety, and Cost-Effectiveness. | Curr Med Sci | 2025 | https://conductscience.org/library/papers/41060358 | PubMed |
| 40595440 | Knowledge, attitudes, and practices of outpatients regarding National centralized drug procurement policy: a multicenter cross-sectional study in North China. | Sci Rep | 2025 | https://conductscience.org/library/papers/40595440 | PubMed |
| 38895618 | The impact of Chinese volume-based procurement on pharmaceutical market concentration. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38895618 | PubMed |
| 38176692 | Comprehensive approach to controlling chronic hepatitis B in China. | Clin Mol Hepatol | 2024 | https://conductscience.org/library/papers/38176692 | PubMed |
| 38042834 | The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial. | Trials | 2023 | https://conductscience.org/library/papers/38042834 | PubMed |
| 37745061 | Problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37745061 | PubMed |
| 37731741 | A quasi-experimental study of the volume-based procurement (VBP) effect on antiviral medications of hepatitis B virus in China. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37731741 | PubMed |
| 37580251 | [Ten-year changes in clinical characteristics and antiviral treatment patterns of chronic hepatitis B in China: a CR-HepB-based real-world study]. | Zhonghua Gan Zang Bing Za Zhi | 2023 | https://conductscience.org/library/papers/37580251 | PubMed |
| 37243297 | The Impact of the Definitions of Clinical Phases on the Profiles of Grey-Zone Patients with Chronic Hepatitis B Virus Infection. | Viruses | 2023 | https://conductscience.org/library/papers/37243297 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35836769
GET https://conductscience.org/api/papers/v1/35836769/references?page=2